2025 American Urological Association (AUA)
AUA 2025 Prostate Cancer
- AUA 2025: A Novel Core Needle Biopsy Instrument Designed for Targeted Biopsy
- AUA 2025: Impact of Prior Holmium Laser Enucleation of the Prostate (HoLEP) on the Accuracy of PI-RADS for Assessing Clinically Significant Prostate Cancer
- AUA 2025: Rizedisben, a Novel Myelin-Binding Fluorophore for Intraoperative Fluorescent Imaging of Nerve Structures: Phase I Trial in Robotic Radical Prostatectomy
- AUA 2025: State-Of-The-Art Lecture: A Perfect Storm: The Timing, Scope, and Spectrum of Radiation-Induced Complications after Prostate Cancer Treatment
- AUA 2025: Ultra-low PSA Response (0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes
AUA 2025 Bladder Cancer
- AUA 2025: Level of Nodal Metastasis in Patients Undergoing Radical Cystectomy and Lymphadenectomy for Muscle-Invasive Urothelial Cancer: Is There Still a Role of Extended Lymphadenectomy in the Post-S1011 Era?
- AUA 2025: Upstaging and Risk Migration with Blue Light Cystoscopy for Non-Muscle-Invasive Bladder Cancer: Results from a Prospective Multicenter Registry
- AUA 2025: Oncologic Outcomes in Patients Undergoing Radical Cystectomy for NMIBC Following BCG Therapy Failure
- AUA 2025: Precystectomy ctDNA Burden is Predictive of Poor Oncological Outcomes
- AUA 2025: Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: Conditional Survival and Long-Term Safety in Patients Treated for ≥1 or ≥2 Years in JAVELIN Bladder 100
AUA 2025 Upper Tract Urothelial Carcinoma
- AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma
- AUA 2025: Long-Term Outcomes of Treatment of Recurrent or New-Onset Low-Grade UTUC with UGN-101, a Mitomycin Reverse Thermal Gel
- AUA 2025: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer: ENLIGHTED Phase 3 Study
- AUA 2025: Postoperative Adjuvant Treatment of HER2-Overexpressing Upper Tract Urothelial Carcinoma with Disitamab Vedotin and Toripalimab: A Real-World Retrospective Study
AUA 2025 Kidney Cancer
- AUA 2025: Active Surveillance for Clinical Stage T1b Renal Masses in a Large Statewide Collaborative.
- AUA 2025: Robotic-Assisted Partial Nephrectomy in Augmented Reality: Reliability of a Neural Network Training Methodology for Automated Renal Parenchyma Recognition (UROCCR 112)
- AUA 2025: Renal Mass Biopsy for Small Renal Masses: A Single Center 20-Year Experience
- AUA 2025: Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitor Combination Therapies for Metastatic Renal Cell Carcinoma with Primary Kidney Tumors
- AUA 2025: Comparison of Clinical Outcomes Between Cabozantinib + Nivolumab and Lenvatinib + Pembrolizumab in Advanced RCC
AUA 2025 Lower Urinary Tract Conditions
- AUA 2025: State-of-the-Art Lecture - What is the Role of the Urologist in Trauma Care in 2025?
- AUA 2025: Crossfire: Controversies in Urology: Battle of the Guidelines: Examining Key Differences in Evidence-Based Urethral Stricture Management.
- AUA 2025: Panel Discussion: Challenging Cases in Recurrent Urinary Tract Infections
- AUA 2025: New Artificial Urinary Sphincter: Results of the First in Man Study at One-Year Post-Activation (SOPHIA Study)
- AUA 2025: Long-Term Outcomes of Rezūm Therapy in a Large, Multi-Centre, International Cohort: 3-Year Analysis of Symptom Relief and Quality of Life in Patients with Benign Prostatic Enlargement
AUA 2025 Sexual Dysfunction
- AUA 2025: Panel Discussion – Contemporary Management of Fournier’s Gangrene (Tissue Sparing Debridement, Early Reconstruction and Discharge Planning)
- AUA 2025: Factors Associated with Elevated Post-Void Residual Urine in Men and Women with Long-Standing Type 1 Diabetes (T1D): The Uro-EDIC Study
- AUA 2025: Predictive Value of Penile Doppler Ultrasound Impairments
- AUA 2025: Erection Function and Bother in Transgender Women Taking Gender Affirming Hormone Therapy and After Pre-Vaginoplasty Bilateral Orchiectomy
- AUA 2025: Second Opinion Cases: Penile Fracture
AUA 2025 Endourology and Stone Disease
- AUA 2025: H2O or H2-No? Is Water Safe to Use in Percutaneous Nephrolithotomy?
- AUA 2025: Robotic Surgery and Patient Safety: A Global Assessment of Technological Malfunctions During Da Vinci X and Xi Procedures
- AUA 2025: Intraoperative Cone Beam Computed Tomography for Detecting Residual Fragments During Percutaneous Nephrolithotomy: One Year Follow-up Results From a Randomized Controlled Trial
- AUA 2025: P2s, Paradigm-Shifting, Practice-changing Clinical Trials in Urology: Randomized Multicenter Trial of Ureteral Stent Placement Versus Stent Omission After Ureteroscopy for Renal Stones
- AUA 2025: The Effect of High-Power Lasers on Renal Temperature During Intrarenal Surgery
AUA 2025 Engineering in Urology Society
- EUS 2025: Robotic Transurethral Bladder Tumor Resection: A New Era Of Natural Orifice Transluminal Endoscopic Surgery
- EUS 2025: Prostate Ductal Anatomy as a Cancer Contrast Mechanism for Ultrasound
- EUS 2025: Improved Control of Renal Pelvis Pressure Using A Prototype Fluid Management System Incorporating Ureteroscope Pressure Feedback
- EUS 2025: High-Precision Detection of Difficult-to-Detect Lesions in Bladder Cancer Diagnosis Using a Lightweight AI Model
- EUS 2025: The First-in-Human Transcontinental Telesurgery Collaboration for High-Intensity Focused Ultrasound: A New Era in Globalizing Focal Cancer Treatment for Prostate Cancer
AUA 2025 Press Releases
- New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
- Three-Year Data of Zenflow’s Spring System Demonstrate Durability of Clinical Benefits For Patients Suffering from BPH
- Bladder Cancer Presentations at AUA 2025: Blue Light Cystoscopy Improves Risk Stratification and Informed Decision Making
- Revi® System Demonstrates Significant and Sustained Quality of Life Benefits Across All Domains for the Majority of Patients with Urgency Urinary Incontinence at 24 Months
- Medtronic Expand URO U.S. Clinical Trial Meets Safety and Effectiveness Primary Endpoints for Hugo™ Robotic-Assisted Surgery System